

Study Protocol Overview

Protocol Id 81
Protocol Name Ho-002_Vasan_Ibalizumab-MacaquePK_Neut
Grant CAVD

Revision 6: Blake Wood Fri Mar 12 15:53:10 GMT-800 2010
Investigator Sandhya Vasani
Species Macaque

Overview

This study aims to measure the neutralizing activity of the anti-HIV mAb ibalizumab detected in macaque serum after administration via two different routes: intravenous (I.V.) and subcutaneous (s.c.).

Note: Blood draws as below

Group A (I.V. ibalizumab): Days 0, 1.5, 2.5, 3, 7, 10

Group B (S.C. ibalizumab): Days 0, 1, 2, 3, 4, 7, 14, 28

Vaccine Design

Immunogens

Name	Type	Dose	Route	HIV Antigens
I.V. ibalizumab	Antibody	2.5 mg/kg	Intravenous (IV)	
s.c. ibalizumab	Antibody	5 mg/kg	Subcutaneous (SC)	

Adjuvants

Name	Dose	Route
N/A		
N/A		

Immunization Protocol

		Immunization Schedule
Group	Count	0 days
A	3	I.V. ibalizumab
B	3	s.c. ibalizumab

Assays

		Assay Schedule							
Assay	Lab	Day 0: 0 days	Day 1: 1 days	Day 2: 2 days	Day3: 3 days	Day 4: 4 days	Day7: 7 days	Day14: 14 days	Day28: 28 days
Neutralizing Anitbodies	Seaman	[x] 100 ul Serum	[x] 100 ul Serum	[x] 2 ml Serum	[x] 100 ul Serum	[x] 100 ul Serum	[x] 100 ul Serum	[x] 100 ul Serum	[x] 100 ul Serum